Envoy Medical (COCH) Registration filing summary

Company overview and business model

• Focuses on innovative, fully implanted hearing devices leveraging natural ear anatomy, with two main products: Esteem FI-AMEI (FDA approved, limited commercial traction) and investigational Acclaim CI (fully implanted cochlear implant).

• Acclaim CI targets adults with severe to profound sensorineural hearing loss not adequately addressed by hearing aids; received FDA Breakthrough Device Designation in 2019.

• Business model centers on developing, obtaining regulatory approval for, and commercializing the Acclaim CI, with plans for U.S. and international expansion post-approval.

• Revenue currently derived from Esteem FI-AMEI implants and replacements; future growth depends on Acclaim CI commercialization.

Financial performance and metrics

• Net loss of $6.5M for Q3 2025 and $17.2M for the nine months ended September 30, 2025; accumulated deficit of $305.7M as of September 30, 2025.

• Annual net loss of $20.8M in 2024, down from $29.9M in 2023; R&D expenses increased to $10.2M in 2024.

• Cash balance of $3.6M as of September 30, 2025; expects to have sufficient funds through February or March 2026, assuming no additional warrant exercises.

• Operations funded primarily through equity, term loans, convertible debt, and recent offerings; substantial doubt exists about ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; may receive up to $20.1M if all warrants are exercised for cash.

• Any proceeds from warrant exercises will be used for general corporate purposes and working capital.

• Recent capital raises include $2.5M (September 2025 Offering) and $4.0M (October 2025 Offering); additional proceeds possible from warrant exercises.